Business description
Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people living with brain disease. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company’s products are targeted at diseases such as depression and anxiety, psychotic disorders, epilepsy and Huntington’s, Alzheimer’s and Parkinson’s diseases.
Management board & Supervisory board
| CEO |
| Dr. Deborah Dunsire |
| Management board |
| Anders Götzsche, Dr. Johan Luthman, Elise Hauge, Jacob Tolstrup, Keld Flintholm Jørgensen, Lars Bang |
| Supervisory board |
| Lars Rasmussen, Dorothea Wenzel, Henrik Sindal Jensen, Jeffrey Berkowitz, Jeremy M. Levin, Lars Holmqvist, Lene Skole-Sørensen, Ludovic Tranholm Otterbein, Rikke Kruse Andreasen, Santiago Arroyo |
Company data
| Name: |
H. Lundbeck A/S |
| Address: |
Ottiliavej 9,DK-2500 Valby |
| Phone: |
+45-3630-1311 |
| Fax: |
+45-3630-1940 |
| E-mail: |
information@lundbeck.com
|
| Internet: |
www.lundbeck.com/ |
| Industry: |
Healthcare |
| Sector: |
Pharmaceutical Industry |
| Sub sector: |
Pharmaceuticals |
| End of financial year: |
12-31 |
| Free Float: |
31.00% |
| IPO date: |
- |
Investor relations
| Name: |
Palle Holm Olesen |
| IR phone: |
+45-3643-2426 |
| IR Fax: |
- |
| IR e-mail: |
investor@lundbeck.com
|
